Literature DB >> 1593590

Chronic idiopathic hyperphosphatasia. Report of a case treated with pamidronate and a review of the literature.

A Spindler1, A Berman, C Mautalen, J Ubios, A E Santini.   

Abstract

We describe the case of a 38-year-old woman with 24 years of progressive skeletal deformities. Radiologic survey showed evidence of generalized skeletal involvement. She presented with secondary osteoarthritis, and her hands showed Heberden's and Bouchard's nodes. Light microscopic examination showed many reversed lines in the trabeculae and increased bone resorption and bone forming areas. On electron microscopic study there were intranuclear inclusions in the osteoclasts. To our knowledge, she is the oldest patient described in the English literature, and the first treated with (3-amino-1-hydroxypropilidene)-1,1 biphosphonate (Pamidronate). She showed a decrease in serum alkaline phosphatase, urinary hydroxyproline. Clinical variables showed good response to medication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1593590

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

1.  Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Ioannis Litsas; Zoe Efstathiadou; Marina Kita; Georgios Arsos; Efstratios Moralidis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  J Bone Miner Metab       Date:  2010-06-09       Impact factor: 2.626

Review 2.  Rare Inherited forms of Paget's Disease and Related Syndromes.

Authors:  Stuart H Ralston; J Paul Taylor
Journal:  Calcif Tissue Int       Date:  2019-02-13       Impact factor: 4.333

3.  Juvenile Paget's disease with paranasal sinus aplasia.

Authors:  Ki Beom Bae; Jae Hwan Kwon; Young Ho Kim; Tae Young Jung; Joong Hwan Cho
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-12-26       Impact factor: 3.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.